-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BxdQefVpgaJZcZuzYGeg+EvJg+NLpglViC6FydEfln+So1as8iGsI91d0P3Gd6c9 MRDcDTVrfvZpUA0zkqszZw== 0001209191-11-009398.txt : 20110214 0001209191-11-009398.hdr.sgml : 20110214 20110214192703 ACCESSION NUMBER: 0001209191-11-009398 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110210 FILED AS OF DATE: 20110214 DATE AS OF CHANGE: 20110214 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DERMA SCIENCES, INC. CENTRAL INDEX KEY: 0000892160 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 232328753 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 214 CARNEGIE CENTER, SUITE 300 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6095144744 MAIL ADDRESS: STREET 1: 214 CARNEGIE CENTER, SUITE 300 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: DERMA SCIENCES INC DATE OF NAME CHANGE: 19940513 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WESSON BRUCE F CENTRAL INDEX KEY: 0001058190 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-13070 FILM NUMBER: 11611394 MAIL ADDRESS: STREET 2: 1827 PACIFIC ST CITY: BROOKLYN STATE: NY ZIP: 11233 FORMER NAME: FORMER CONFORMED NAME: WESSON BRUCE T DATE OF NAME CHANGE: 19980319 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2011-02-10 0 0000892160 DERMA SCIENCES, INC. DSCI 0001058190 WESSON BRUCE F C/O GALEN MANAGEMENT, L.L.C. 680 WASHINGTON BLVD. STAMFORD CT 06901 1 0 0 0 Common Stock 2011-02-10 4 S 0 50000 12.5589 D 151772 I See FN Common Stock 2011-02-11 4 S 0 78220 12.5248 D 73552 I See FN Common Stock 3125 D The shares were sold as follows: 45,669 by Galen Partners III, L.P. ("Galen III"), 4,144 by Galen Partners International III, L.P. ("Galen International III") and 187 by Galen Employee Fund III, L.P. ("Employee Fund III"). The shares were sold at prices between $12.50 and $12.66. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares are held as follows: 138,624 by Galen III, 12,578 by Galen International III and 570 by Employee Fund III. Claudius, L.L.C. ("Claudius") serves as the sole General Partner of Galen III and Galen International III and has sole voting and invetment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Wesson Enterprises, Inc. ("Wesson") serves as the sole General Partner of Employee Fund III and has sole voting and investment control over the shares held by such fund and may be deemed to beneficially own the shares held by such fund. The Reporting Person is a member of Claudius and the sole shareholder of Wesson. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of his pecuniary interest therein. The shares were sold as follows: 71,444 by Galen III, 6,483 by Galen International III and 293 by Employee Fund III. The shares were sold at prices between $12.2833 and $12.63. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares are held as follows: 67,180 by Galen III, 6,095 by Galen International III and 277 by Employee Fund III. Claudius serves as the sole General Partner of Galen III and Galen International III and has sole voting and invetment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Wesson serves as the sole General Partner of Employee Fund III and has sole voting and investment control over the shares held by such fund and may be deemed to beneficially own the shares held by such fund. The Reporting Person is a member of Claudius and the sole shareholder of Wesson. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of his pecuniary interest therein. /s/ Bruce Wesson 2011-02-14 -----END PRIVACY-ENHANCED MESSAGE-----